Search Results - D. V. Nebieridze

Refine Results
  1. 1
    COMMENTS TO THE PAPER «RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS»

    COMMENTS TO THE PAPER «RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS» by D. V. Nebieridze

    Published 2015-12-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Hyperuricemia a New Cardiovascular Risk Factor

    Hyperuricemia a New Cardiovascular Risk Factor by D. V. Nebieridze

    Published 2020-03-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    COMMENTS ON NEW EUROPEAN GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION

    COMMENTS ON NEW EUROPEAN GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION by D. V. Nebieridze

    Published 2016-01-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    SYSTOLIC ARTERIAL HYPERTENSION: THE PLACE OF ANGIOTENSIN II RECEPTOR BLOCKERS

    SYSTOLIC ARTERIAL HYPERTENSION: THE PLACE OF ANGIOTENSIN II RECEPTOR BLOCKERS by D. V. Nebieridze

    Published 2002-02-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    CALCIUM ANTAGONISTS IN CLINICAL PRACTICE: FOCUS ON METABOLIC AND VASCULAR EFFECTS

    CALCIUM ANTAGONISTS IN CLINICAL PRACTICE: FOCUS ON METABOLIC AND VASCULAR EFFECTS by D. V. Nebieridze

    Published 2015-12-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II

    Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II by A. S. Safaryan, D. V. Nebieridze

    Published 2021-10-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM?

    ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM? by D. V. Nebieridze, A. S. Safarian

    Published 2016-01-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Imidazoline receptor agonists: more than blood pressure reduction?

    Imidazoline receptor agonists: more than blood pressure reduction? by D. V. Nebieridze, S. V. Nedogoda

    Published 2006-04-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Place of imidazoline receptor agonists in the treatment of hypertension

    Place of imidazoline receptor agonists in the treatment of hypertension by D. V. Nebieridze, A. S. Safaryan

    Published 2022-01-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?

    IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES? by D. V. Nebieridze, T. V. Kamyshova

    Published 2015-12-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    High-risk patients: modern treatment strategy

    High-risk patients: modern treatment strategy by D. V. Nebieridze, A. Meliya

    Published 2010-12-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    New potential of ACE inhibitors in clinical practice

    New potential of ACE inhibitors in clinical practice by D. V. Nebieridze, A. S. Safaryan

    Published 2010-10-01
    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    PREVALENCE OF HYPERURICEMIA AMONG PATIENTS WITH METABOLIC SYNDROME: RESULTS OF THE STUDY IN REAL CLINICAL PRACTICE

    PREVALENCE OF HYPERURICEMIA AMONG PATIENTS WITH METABOLIC SYNDROME: RESULTS OF THE STUDY IN REAL CLINICAL PRACTICE by D. V. Nebieridze, N. V. Dolgushina

    Published 2017-12-01
    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    Uric Acid as a Risk Factor for Cardiovascular Diseases

    Uric Acid as a Risk Factor for Cardiovascular Diseases by A. S. Safaryan, A. S. Lishuta, D. V. Nebieridze

    Published 2022-09-01
    Get full text
    Article

    Save to List
    Saved in:
  15. 15
    The Role of Magnesium in the Development of Cardiovascular Diseases and the Possibility of their Prevention and Correction with Magnesium Preparations (Part 2)

    The Role of Magnesium in the Development of Cardiovascular Diseases and the Possibility of their Prevention and Correction with Magnesium Preparations (Part 2) by A. S. Safaryan, V. S. Sargsyan, D. V. Nebieridze

    Published 2020-07-01
    Get full text
    Article

    Save to List
    Saved in:
  16. 16
    Correction of Hypercholesterolemia in Primary and Secondary Prevention of Cardiovascular Diseases: Features and Controversial Issues

    Correction of Hypercholesterolemia in Primary and Secondary Prevention of Cardiovascular Diseases: Features and Controversial Issues by N. M. Akhmedzhanov, D. V. Nebieridze, A. S. Safaryan

    Published 2019-01-01
    Get full text
    Article

    Save to List
    Saved in:
  17. 17
    Beta-adrenoblockers in clinical practice: is there any difference?

    Beta-adrenoblockers in clinical practice: is there any difference? by D. V. Nebieridze, A. Meliya, G. R. Kulieva

    Published 2007-06-01
    Get full text
    Article

    Save to List
    Saved in:
  18. 18
    IS IT POSSIBLE TO IMPROVE THE ADHERENCE TO TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN PATIENTS WITHOUT CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS?

    IS IT POSSIBLE TO IMPROVE THE ADHERENCE TO TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN PATIENTS WITHOUT CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS? by A. А. Sarycheva, D. V. Nebieridze, T. V. Kamyshova

    Published 2017-11-01
    Get full text
    Article

    Save to List
    Saved in:
  19. 19
    Rosuvastatin microcirculatory effects in patients with dyslipidemia and arterial hypertension

    Rosuvastatin microcirculatory effects in patients with dyslipidemia and arterial hypertension by D. V. Nebieridze, G. R. Kulieva, V. A. Vygodin

    Published 2006-08-01
    Get full text
    Article

    Save to List
    Saved in:
  20. 20
    Patients’ education as a factor for arterial hypertension effective control – NOCTURNE Program

    Patients’ education as a factor for arterial hypertension effective control – NOCTURNE Program by A. M. Kalinina, R. G. Oganov, D. V. Nebieridze

    Published 2006-06-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: